The transaction marks a significant milestone for both VERAXA and Xlife Sciences, representing the first NASDAQ listing of a portfolio company and highlighting the effectiveness of Xlife Sciences’ incubation model in advancing breakthrough life sciences innovations to global capital markets. Through the transaction, VERAXA has established a strengthened financial position, including a USD 27.5 million senior secured note financing and a share purchase agreement of up to USD 50 million. The proceeds will support the continued advancement of VERAXA's oncology pipeline based on its proprietary BiTAC platform, driving its progression toward clinical development and industrial partnerships.

VERAXA is focused on the development of next-generation cancer therapies, including bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs). Its BiTAC platform enables highly selective, conditionally activated therapies designed to target cancer cells while sparing healthy tissue, with the potential to significantly improve therapeutic outcomes. Recent data presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrated promising preclinical results supporting the platform’s potential to deliver enhanced safety and efficacy compared to conventional approaches.

Oliver R. Baumann, CEO of Xlife Sciences AG and Chairman of the Board of VERAXA Biotech AG, commented: «Taking VERAXA public on NASDAQ represents a defining moment for Xlife Sciences. It validates our strategy of identifying, developing, and scaling high-potential scientific innovations into globally competitive companies. We are proud to have supported VERAXA from its early development stage to this important milestone and look forward to continued value creation as the company advances its pipeline.»

The successful listing underscores Xlife Sciences’ ability to translate cutting-edge research into investable, high-growth companies addressing significant unmet medical needs. VERAXA’s progress demonstrates the scalability of Xlife Sciences’ platform across biotechnology and other key focus areas, including medical technology, digital health, and artificial intelligence.